Cargando…

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study

BACKGROUND: International consensus recognises four medulloblastoma molecular subgroups: WNT (MB(WNT)), SHH (MB(SHH)), group 3 (MB(Grp3)), and group 4 (MB(Grp4)), each defined by their characteristic genome-wide transcriptomic and DNA methylomic profiles. These subgroups have distinct clinicopatholo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwalbe, Edward C, Lindsey, Janet C, Nakjang, Sirintra, Crosier, Stephen, Smith, Amanda J, Hicks, Debbie, Rafiee, Gholamreza, Hill, Rebecca M, Iliasova, Alice, Stone, Thomas, Pizer, Barry, Michalski, Antony, Joshi, Abhijit, Wharton, Stephen B, Jacques, Thomas S, Bailey, Simon, Williamson, Daniel, Clifford, Steven C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489698/ https://www.ncbi.nlm.nih.gov/pubmed/28545823 http://dx.doi.org/10.1016/S1470-2045(17)30243-7

Ejemplares similares

Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study
por: Hill, Rebecca M, et al.
Publicado: (2020)

MBRS-44. TIME, PATTERN AND OUTCOME OF MEDULLOBLASTOMA RELAPSE ARE ASSOCIATED WITH TUMOUR BIOLOGY AT DIAGNOSIS AND UPFRONT THERAPY: A COHORT STUDY
por: Hill, Rebecca, et al.
Publicado: (2020)

Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics
por: Crosier, Stephen, et al.
Publicado: (2021)

MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS
por: Richardson, Stacey, et al.
Publicado: (2020)

Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development
por: Williamson, Daniel, et al.
Publicado: (2022)

Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
por: Richardson, Stacey, et al.
Publicado: (2021)

OMIC-06. MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA VIA LOW-DEPTH WHOLE GENOME BISULFITE SEQUENCING
por: Thompson, Dean, et al.
Publicado: (2021)

PATH-06. Molecular subgrouping of medulloblastoma via low-depth whole genome bisulfite sequencing
por: Thompson, Dean, et al.
Publicado: (2022)

Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development
por: Danilenko, Marina, et al.
Publicado: (2022)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease
por: Hill, Rebecca M., et al.
Publicado: (2015)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION
por: Goddard, Jack, et al.
Publicado: (2021)

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance
por: Lindsey, Janet C., et al.
Publicado: (2014)

MBRS-59. SINGLE-CELL WHOLE-GENOME SEQUENCING DISSECTS INTRA-TUMOURAL GENOMIC HETEROGENEITY AND CLONAL EVOLUTION IN CHILDHOOD MEDULLOBLASTOMA
por: Danilenko, Marina, et al.
Publicado: (2020)

MBRS-69. METABOLITE PROFILING OF SHH MEDULLOBLASTOMA IDENTIFIES A SUBSET OF CHILDHOOD TUMOURS ENRICHED FOR HIGH-RISK MOLECULAR BIOMARKERS AND CLINICAL FEATURES
por: Bennett, Christopher, et al.
Publicado: (2020)

MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding
por: Goddard, Jack, et al.
Publicado: (2022)

MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile
por: Alaña, Lide, et al.
Publicado: (2022)

Molecular subgroups of medulloblastoma: the current consensus
por: Taylor, Michael D., et al.
Publicado: (2011)

Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia
por: Gabriel, Alem S, et al.
Publicado: (2015)

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
por: Goddard, Jack, et al.
Publicado: (2023)

MEDB-31. THE CLINICAL SIGNIFICANCE OF EXTENT OF RESECTION IN MEDULLOBLASTOMA
por: Keeling, Claire, et al.
Publicado: (2022)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray
por: Hacking, James P.R., et al.
Publicado: (2023)

Novel mutations target distinct subgroups of medulloblastoma
por: Robinson, Giles, et al.
Publicado: (2012)

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
por: Goschzik, Tobias, et al.
Publicado: (2018)

Current medulloblastoma subgroup specific clinical trials
por: Thompson, Eric M., et al.
Publicado: (2020)

Subgroup-specific roles of primary cilia in medulloblastoma
por: Marino, Silvia
Publicado: (2022)

MEDB-67. Subgroup specific analysis of cellular metabolism in medulloblastoma
por: Funke, Viktoria, et al.
Publicado: (2022)

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
por: Clifford, Steven C., et al.
Publicado: (2015)

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
por: Remke, Marc, et al.
Publicado: (2013)

Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures
por: Schwalbe, E. C., et al.
Publicado: (2017)

Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity
por: Grabovska, Yura, et al.
Publicado: (2020)

G-protein coupled receptor expression patterns delineate medulloblastoma subgroups
por: Whittier, Kelsey L, et al.
Publicado: (2013)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma
por: Park, Ae Kyung, et al.
Publicado: (2019)

OMIC-01. THE LANDSCAPE OF EXTRACHROMOSOMAL CIRCULAR DNA IN MEDULLOBLASTOMA SUBGROUPS
por: Chapman, Owen, et al.
Publicado: (2021)

Role of MicroRNAs in the Development and Progression of the Four Medulloblastoma Subgroups
por: Bevacqua, Emilia, et al.
Publicado: (2021)

MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture
por: Willard, Nicholas, et al.
Publicado: (2022)

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
por: Kool, Marcel, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_m1e9fv6t42nilubogtatpg0f1b